Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Amrubicin

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Amrubicin: Sponsors, patents, clinical trial progress

Amrubicin is an investigational drug.

There have been 19 clinical trials for Amrubicin. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2008.

The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Breast Neoplasms. The leading clinical trial sponsors are Celgene Corporation, Celgene, and SCRI Development Innovations, LLC.

Recent Clinical Trials for Amrubicin
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung CancerOno Pharmaceutical Co. LtdPhase 3
Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung CancerBristol-Myers SquibbPhase 3
A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based ChemotherapyTaiho Pharmaceutical Co., Ltd.Phase 2

See all Amrubicin clinical trials

Clinical Trial Summary for Amrubicin

Top disease conditions for Amrubicin
Top clinical trial sponsors for Amrubicin

See all Amrubicin clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.